Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Cha...
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)
About this item
Full title
Author / Creator
ROCKET AF Steering Committee and Investigators , Washam, Jeffrey B. , Hellkamp, Anne S. , Lokhnygina, Yuliya , Piccini, Jonathan P. , Berkowitz, Scott D. , Nessel, Christopher C. , Becker, Richard C. , Breithardt, Günter , Fox, Keith A.A. , Halperin, Jonathan L. , Hankey, Graeme J. , Mahaffey, Kenneth W. , Singer, Daniel E. and Patel, Manesh R.
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Non-dihydropyridine calcium channel blockers (non-DHP CCBs) possess combined P-glycoprotein and moderate CYP3A4 inhibition, which may lead to increased exposure of medications that are substrates for these metabolic pathways, such as rivaroxaban. We evaluated the use and outcomes of non-DHP CCBs in patients with atrial fibrillation (AF) in Rivaroxa...
Alternative Titles
Full title
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)
Authors, Artists and Contributors
Author / Creator
Washam, Jeffrey B.
Hellkamp, Anne S.
Lokhnygina, Yuliya
Piccini, Jonathan P.
Berkowitz, Scott D.
Nessel, Christopher C.
Becker, Richard C.
Breithardt, Günter
Fox, Keith A.A.
Halperin, Jonathan L.
Hankey, Graeme J.
Mahaffey, Kenneth W.
Singer, Daniel E.
Patel, Manesh R.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1913398252
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1913398252
Other Identifiers
ISSN
0002-9149
E-ISSN
1879-1913
DOI
10.1016/j.amjcard.2017.05.026
